KRAS signalling in malignant pleural mesothelioma
A. Marazioti, A. Krontira, M. A. Pepe, M. Iliopoulou, D. E. Wagner, H. Papadaki, S. G. Antimisiaris, I. Psallidas, M. Spella, I. Lilis, I. Giopanou, M. Vreka, C. Blanquart, M. Gregoire, S. Deshayes, , G. T. Stathopoulos
This study identifies KRAS mutations as a significant driver in human malignant pleural mesothelioma and demonstrates their role in disease initiation and treatment response in mouse models.
bioRxiv · Oct 22, 2020 · PreprintPhysiology